doxorubicin,sotigalimab,cgt9486
apexigen,cogent biosciences
['doxorubicin', 'apex', 'sotigalimab', 'sarcoma', 'apexigen', '$apgn']
$apgn apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of clinical oncology (asco) 2023 annual meeting 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities